Shenzhou Cell announced that the State Drug Administration (NMPA) has officially approved the listing of the company's new anti-CD20 monoconec antibody repaturumab (Ampingxi ®).

On August 30, China Cell Engineering Co.

Lymphoma is one of the earliest tumors of the blood system, and it is the highest incidence of blood tumors, and the incidence is increasing
year by year.
According to the latest GBD (Global Burden of Disease) data analysis, the number of new cases of lymphoma in China reached 100,000 in 2019, and the number of lymphoma patients in China is estimated to reach 470,000, and the burden of lymphoma disease in China is on the rise
.
Diffuse large B-cell lymphoma is a curable lymphoma, accounting for about 50%
of B-cell lymphoma in China.
Anti-CD20 monoclonal antibody is the cornerstone drug
of B-cell lymphoma treatment.

The listing of Ampinghi ® (repaturumab) will further enhance the accessibility of anti-CD20 monoclonal antibody, benefit more Chinese lymphoma patients, and help achieve
the goal of "Healthy China 2030".

About Shenzhou Cells

China Cell Engineering Co.
, Ltd.
is a leading innovative biopharmaceutical R&D and industrialization development company, under the leadership of internationally renowned biopharmaceutical expert Dr.
Xie Liangzhi, long-term focus on malignant tumors, autoimmune diseases, infectious diseases and genetic diseases and other therapeutic and preventive fields of biological drug products research and development and industrialization
。 After more than ten years of biopharmaceutical technology accumulation and innovation, the company has established a high-efficiency, high-throughput technology platform covering the whole chain of biopharmaceutical research and development and production, and independently developed a diversified and distinctive pipeline of monoclonal antibodies, recombinant proteins, vaccines and other biopharmaceutical products, is committed to providing high-quality, low-cost treatment options for domestic and international patients, and will establish a leading biopharmaceutical brand and build an internationally competitive Chinese biopharmaceutical enterprise as the company's development vision
.